1. Introduction {#sec1}
===============

Amantadine was developed as a treatment for influenza A infection, and later found to exhibit anti-parkinsonian effects.[@bib1] Since that discovery in 1969, it has been widely used in the management of Parkinson\'s disease.

There have been several reports regarding amantadine-associated ocular complications, such as superficial punctate keratitis, corneal endothelial dysfunction, epithelial edema, and stromal edema.[@bib2], [@bib3], [@bib4], [@bib5] However, there have been no reports regarding amantadine-induced deposits in corneal epithelial cells.

Here, we describe a patient who exhibited bilateral corneal epithelial opacities following treatment of Parkinson\'s disease with amantadine.

2. Case report {#sec2}
==============

An 81-year-old woman with bilateral corneal opacities was referred to the Hiroshima University hospital. At the first visit, her corrected visual acuity was 0.8 in both eyes. Intraocular pressures were 15 mmHg in the right eye and 16 mmHg in the left eye. Slit-lamp examination revealed bilateral belt-shaped epithelial opacities in the central part of the cornea ([Fig. 1](#fig1){ref-type="fig"}). She had no dry eye findings, such as superficial punctate keratitis or short tear break-up times. There were no signs of inflammatory findings in the anterior chamber, vitreous or retina. The endothelial cell density at the center cornea was 3017 cells/mm^2^ in the right eye and 2297 cells/mm^2^ in the left eye. On anterior segment optical coherence tomography examination, there was no opacity and edema in the corneal stroma of either eye ([Fig. 2](#fig2){ref-type="fig"}). Confocal biomicroscopy showed high-density plaques in the basal layer of corneal epithelial cells in both eyes ([Fig. 3](#fig3){ref-type="fig"}).Fig. 1Slit-lamp examination of the anterior segment at the first visit. There were intra-epithelial opacities in the right cornea (a, c) and left cornea (b, d). There was no fluorescein staining in either cornea (c, d).Fig. 1Fig. 2Anterior segment optical coherence tomography examination of the right cornea (a) and left cornea (b) at the first visit. There was no opacity or edema in either cornea.Fig. 2Fig. 3Confocal biomicroscopic findings of the right cornea (a, b) and left cornea (c, d) at the first visit. The basal layers of corneal epithelial cells around the border between the opaque and clear portions of the cornea are shown, and the dotted line represents the border between the normal and abnormal areas. Epithelial cells in the upper area were normal. In the lower area, reflective abnormal epithelial cells were observed (a, c). In the basal layer of the opaque cornea, highly reflective round shaped deposits were observed (b, d) (arrow head).Fig. 3

The patient\'s medical history included Parkinson\'s disease, insomnia, hypertension, hypercholesterolemia, osteoporosis, hypothyroidism, and constipation. She was taking amantadine, clotiazepam, milnacipran, carvedilol, lovastatin, levothyroxine, alfacalcidol, alendronate, rabeprazole, and irsogladine. Amantadine had been started 9 years prior for treatment of Parkinson\'s disease. Her daily dose of amantadine was 300 mg. She had no history of the use of any eye drops. The patient\'s ocular history was unremarkable, and she had no family history of corneal disease.

We suspected that the corneal opacities might be associated with the use of systemic drugs. Among the drugs that the patient was taking, amantadine has reportedly induced several corneal complications; thus, amantadine was suspected as the probable cause of her corneal opacities. After consultation with her neurologist, amantadine therapy was discontinued. Two months after discontinuation of amantadine, the patient\'s corneal opacities had disappeared ([Fig. 4](#fig4){ref-type="fig"}), and visual acuity had returned to 1.0 in both eyes. Furthermore, there were no high-density deposits in corneal epithelial cells on confocal biomicroscopy ([Fig. 5](#fig5){ref-type="fig"}). The patient was returned to her referring ophthalmologist for continued follow-up care.Fig. 4Slit-lamp examination of the anterior segment at 2 months after discontinuation of amantadine. Corneal intra-epithelial opacities disappeared in the right cornea (a, c) and left cornea (b, d). There was no fluorescein staining in either cornea (c, d).Fig. 4Fig. 5Confocal biomicroscopy of the right cornea (a) and the left cornea (b) at 2 months after discontinuation of amantadine. These images show almost the same areas as seen in [Fig. 3](#fig3){ref-type="fig"}. There were no high-density deposits in the corneal epithelial cells in either cornea.Fig. 5

3. Discussion {#sec3}
=============

Amantadine has been reported to cause various corneal complications, such as superficial punctate keratitis, corneal endothelial dysfunction, and corneal edema.[@bib2], [@bib3], [@bib4], [@bib5] However, these reports did not clearly show that amantadine can induce deposits in corneal epithelial cells. We report here on amantadine-induced deposits in corneal epithelial cells; notably, confocal biomicroscopy was useful for observation of highly reflective deposits in the basal layer of corneal epithelium.

A number of systemic drugs, such as amiodarone, are known to induce deposits in corneal epithelial cells[@bib6]; these drugs tend to induce a vortex pattern of deposits. This vortex pattern of corneal deposits is the result of the centripetal migration of cells from the limbal stem cells to the center of the cornea. The epithelial cells in the central area of the cornea are exposed to drugs for a longer period of time, and tend to form opacities due to accumulation of drug inside affected cells. Therefore, in the present case, we speculate that the corneal opacities appeared in the central area of the cornea due to drug exposure.

The patient in the present case, however, did not show a vortex pattern of corneal deposits, but rather a belt-shaped epithelial opacity at the center of each cornea. The mechanism for the formation of amantadine-induced deposits may differ from that in amiodarone-induced keratopathy. The belt-shaped opacities matched with the eyelid apertures, thus the exposure to air may have caused some kind of reaction and induced belt-shaped opacities.

We propose the following two possible mechanisms for the formation of amantadine-induced corneal deposits. First, phospholipidosis (PLD) in the cells of the corneal epithelium may be related to the occurrence of amiodarone-induced keratopathy; notably, amiodarone is the most widely studied systemic drug that causes corneal epithelial changes. Amiodarone belongs to the family of cationic-amphiphilic drugs (CADs), and has been shown to induce PLD in various organs.[@bib8] The cornea is a potential target of PLD. Corneal PLD is termed drug-induced keratopathy and involves formation of corneal deposits. The precise mechanism for CAD-induced corneal toxicity is not well-known, but PLD in the cells of corneal epithelium may be related to amiodarone-induced toxicity. In addition, other CADs (e.g., chloroquine, chlorpromazine and indomethacin) have been reported to cause corneal PLD.[@bib9]^,^[@bib10] Amantadine also belongs on the list of CADs,[@bib11] and has been reported to cause phospholipid storage in various organs and tissues in rats, as well as in cultured cells.[@bib12] It is not yet known whether amantadine causes phospholipid storage in corneal epithelial cells, but amantadine might be associated with drug-induced PLD, similar to the effects of other CADs.

There have also been several reports regarding confocal biomicroscopic observations of amiodarone-induced keratopathy.[@bib13]^,^[@bib14] Those studies showed highly reflective epithelial cells, which were morphologically similar to those in the present case. However, some of the highly reflective materials inside the epithelial cells in the present case were hard to explain, because they varied in contrast and shape. A possible reason is that different doses of amantadine or different densities of the cytoplasmic deposits may affect the reflective materials. It is also possible that the highly reflective materials that did not seem to be located inside the epithelial cells may be the result of epithelial cell degeneration after the accumulation of amantadine. However, the resolution of the current confocal biomicroscope limited our ability to obtain a more-detailed image of the morphology of the corneal epithelial cells. Further studies with a larger number of patients are needed to be able to understand the morphological mechanisms.

Second, organic cation transporters (OCTs) may be related to amantadine-induced keratopathy. OCTs constitute broad-specificity transporters for the excretion of endogeneous organic cations, as well as the uptake, elimination, and distribution of cationic drugs, toxins, and environmental waste products. OCT1 and OCT2 are members of a solute carrier superfamily of OCTs; notably, OCT1 and OCT2 are primarily expressed in the basolateral membrane of renal tubules, where they aid in renal secretion and reabsorption.[@bib15] Structurally, amantadine is a substrate of both OCT1 and OCT2.[@bib16] Furthermore, several transporters are expressed in various ocular tissues, such as the cornea, iris, ciliary body, conjunctiva, and retina; in these tissues, facilitate the transport of many drugs, toxins, and endogenous compounds.[@bib17] OCT1 mRNA has been detected in human cornea.[@bib18] These findings suggest that OCTs may contribute to the transport of amantadine into corneal epithelial cells.

Additionally, the patient was using many drugs, and the interactions of these drugs or their metabolites may have contributed to the formation of corneal deposits. Further studies are needed to elucidate the underlying mechanism in amantadine-induced formation of corneal deposits.

4. Conclusions {#sec4}
==============

Amantadine can induce deposits in corneal epithelial cells, and should be considered in the differential diagnosis of corneal opacity.
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